Physician profile
Laurel Lenee Kelley
NPI 1982167102
$846.91
in general payments reported to CMS, 2019-2025
17 companies · $817 in 2025
The $817 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $30.33 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $846.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $260.31 | 2025 | Valtoco |
| Ucb, INC. | $72.50 | 2024-2025 | Fintepla, Briviact |
| Jazz Pharmaceuticals INC. | $67.50 | 2025 | |
| Abbvie INC. | $56.97 | 2025 | |
| Upsher-Smith Laboratories LLC | $51.25 | 2025 | |
| Sk Life Science, INC. | $47.37 | 2025 | |
| Acadia Pharmaceuticals INC | $45.94 | 2025 | Nuplazid, Daybue |
| Novartis Pharmaceuticals Corporation | $33.58 | 2025 | |
| Otter Pharmaceuticals, LLC | $29.79 | 2025 | Sympazan |
| Pfizer INC. | $28.55 | 2025 | |
| Biogen, INC. | $26.29 | 2025 | Vumerity, Tysabri |
| Argenx US, INC. | $25.00 | 2025 | Vyvgart Hytrulo |
| Emd Serono, INC. | $23.17 | 2025 | |
| Aucta Pharmaceuticals, INC. | $21.97 | 2025 | Motpoly Xr |
| Alexion Pharmaceuticals, INC. | $20.76 | 2025 | Koselugo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $18.30 | 2025 | Crexont |
| Ipsen Biopharmaceuticals, INC | $17.66 | 2025 | Dysport |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurel Kelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.